

Program at a Glance

Tuesday, May 10, 2022

All times are in Eastern Time.

- 7:00 – 8:00 **Breakfast** (RIVERWALK)
- 8:00 - 8:15 **Welcome** - Samantha Masterson, President, and CEO, MGFA and Brian Gladden, Chair, Board of Directors, MGFA (REGENCY BALLROOM)
- 8:15 – 9:05 **Session 1- Rationale for Therapeutics in Development** (REGENCY BALLROOM) (Same zoom link as above)
Chair: Nils Erik Gilhus, MD, PhD, University of Bergen, Norway
- 8:15 – 8:35 **Complement Inhibition: From Basics to RCT Data**, Saiju Jacob, MD, PhD, University of Birmingham, UK
- 8:35 – 8:55 **Targeting FcRn for Therapy**, Sally Ward, MD, University of Southampton, UK
- Question & Answer
- 9:05 – 10:00 **Keynote Speaker** (REGENCY BALLROOM) (Same zoom link as above)
Introduction: Carolina Barnett-Tapia, MD, PhD, Toronto General Hospital, Canada
- 9:10 – 9:50 **Keynote Speaker:** Angela Vincent, MBBS (Hon PHD Bergen), FRCPath, FMedSci, FRS, University of Oxford, UK
- Question & Answer
- 10:00 – 10:30 **Coffee Break** (RIVERWALK)
- 10:30 – 12:00 **Session 2: Other Therapeutics** (REGENCY BALLROOM)
Chair: Volkan Granit, MD, University of Miami, US
- 10:30 – 10:50 **B Cell Depletion: Mechanisms and RCT Data**, Richard Nowak, MD, MS, Yale School of Medicine, US
- 10:50 – 11:10 **CAR-T Therapy for AChRAb positive MG**, Volkan Granit, MD, University of Miami, US
- 11:10 – 11:30 **Hinge-Deleted IgG4 Blocker Therapy for AChR MG**, Mario Losen, PhD, Maastricht University, Netherlands
- 11:30 – 11:50 **MuSK CAAR-T**, Aimee Payne, MD, PhD, Penn Medicine, US
- Question & Answer

12:00 - 13:30 **Lunch Break** (RIVERWALK)

13:30 – 15:00 **Session 3: Update in MG Immunopathogenesis** (REGENCY BALLROOM)

Chair: Kevin O'Connor, PhD, Yale School of Medicine, US

13:30 – 13:50 **Complement and Autoimmune Disease**, Jeffrey Bennett, MD, PhD, UCHealth Sue Anschutz-Rodgers Eye Center, US

13:50 – 14:10 **MuSK B Cells (MGNet)**, Kevin O'Connor, PhD, Yale School of Medicine, US

14:10 – 14:30 **Single-cell Profiling in Myasthenia Gravis**, Bettina Schreiner, MD, PhD, University of Zurich, Switzerland

14:30 – 14:50 **Targeting IL-23 Amerliorates Tymic and Neuromuscular Defects in MG**, Nadine Dragin, PhD, Sorbonne Université, France

Question & Answer

15:00 - 15:30 **Coffee Break** (RIVERWALK)

15:30 – 16:40 **Session 4: Autoantibodies** (REGENCY BALLROOM)

Chair, Maartje Huijbers, PhD, Leiden University Medical Centre, Netherlands

15:30 – 15:50 **MuSK IgG4 Pathogenicity, Glycosylation**, Maartje Huijbers, PhD, Leiden University Medical Centre, Netherlands

15:50 – 16:10 **Identification of Rare Membrane Antigen Specific Human B Cells**, Nicholas Sanderson, PhD, University of Basel, Switzerland

16:10 – 16:20 **Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity In Patients With Myasthenia Gravis**, Abeer Obaid, Yale University of Medicine, US

16:20 – 16:40 **A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies**, JJ Plomp, PhD, Leiden University Medical Centre, Netherlands

Question & Answer

16:45 – 17:15 **Ancillary Session Sponsored by argenx – Together We Discover: Redefining Immunology with and for the gMG Community**, Luc Truyen, Chief Medical Officer, argenx (ORCHID ABC)

18:00 - 19:30 **Poster Session 1** (REGENCY BALLROOM)

19:30 **Welcome Reception** (RIVERWALK)

Wednesday, May 11, 2022

- 7:00 – 8:00 **Breakfast (RIVERWALK)**
Basic Science Trainee Breakfast (HIBISCUS A)
- 8:00 **Welcome** Carolina Barnett-Tapia, MD, PhD, Toronto General Hospital, Canada for Clinical Sessions (ORCHID ABC); Kevin O'Connor, PhD, Yale University of Medicine, US for Basic Science Sessions (REGENCY BALLROOM)
- 8:05 – 10:00 **Parallel Session 1A: International views/Challenging Cases (ORCHID ABC)**
Chair, Carolina Barnett-Tapia, MD, PhD, Toronto General Hospital, Canada
Panelists: Ha Young Shin, MD, PhD, Yonsei University College of Medicine, Korea
Janine Heckmann, MD, University of Cape Town, So Africa
Valeria Salutto, MD, Universidad de Buenos Aires, Argentina
Dong Dong, PhD, The Chinese University of Hong Kong, Hong Kong
Fatmah Al-Zahmi, MD, Mediclinic Middle East, United Arab Emirates
Question and Answer
- 8:05 – 10:00 **Parallel Session 1B: Biomarkers (REGENCY BALLROOM)**
Chair, Linda Kusner, PhD, George Washington University, Washington DC, US
- 8:00 – 8:20 **Biomarker Development, Methodological Challenges**, Gary Cutter, PhD, University of Alabama at Birmingham
- 8:20 – 8:40 **Survivin**, Linda Kusner, PhD, George Washington University, Washington DC, US
- 8:40 – 9:00 **Treatment Predictive Metabolomic Biomarkers for Myasthenia Gravis**, Henry Kaminski, MD, George Washington University, Washington DC, US
- 9:00 – 9:20 **Circulating microRNA in MG**, Anna Punga, MD, PhD, Uppsala University, Sweden
- 9:20 – 9:40 **Biomarker Response to THX**, Sonia Berrih-Aknin, PhD, Sorbonne Université, France
Question & Answer
- 10:00 - 10:30 **Coffee Break (RIVERWALK)**
- 10:30 – 12:10 **Parallel Session 2A: Updates in MG Management (ORCHID ABC)**

Chair, Ali Habib, MD, University of California, Irvine, US

10:30 – 10:50 **Diagnostic Challenges**, Robert De Meel, MD, Leiden University Medical Centre, Netherlands

10:50 – 11:10 **Management Issues, Refractory Myasthenia**, Ali Habib, MD, University of California, Irvine, US

11:10 – 11:30 **Updates in LEMS and Paraneoplastic NMJ disorders**, Jan Verschuuren, MD, Leiden University Medical Centre, Netherlands

11:30 – 11:50 **Ocular MG**, Sui Wong, MD, Moorfields Eye Hospital; Guy's and St Thomas' Hospitals, UK

Question & Answer

10:30 – 12:10 **Parallel Session 2B: MG Pathophysiology and Thymus** (REGENCY BALLROOM)

Chair: Rozen Le Panse, PhD, Sorbonne Université, Paris

10:30 – 10:50 **Role of Endogenous Nucleic Acids in Interferon Type 1 Signature in EOMG**, Rozen Le Panse, PhD, Sorbonne Université, Paris

10:50 – 11:10 **miR-146a in MG Thymus**, Paola Cavalcante, PhD, Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy

11:10 – 11:30 **NMJ Function and Safety Factor**, William Phillips, PhD, University of Sydney, Australia

11:30 – 11:50 **MuSK is a BMP Co-Receptor**, Justin Fallon, PhD, Brown University, US

Question & Answer

12:10 - 13:30 **Lunch** (RIVERWALK)

13:30 – 15:10 **Session 3: Congenital MG/Pediatric MG** (REGENCY BALLROOM)

Chair: David Beeson, MA, PhD, Nuffield Department of Clinical Neurosciences, UK

13:30 – 13:50 **Updates on CMS**, Ricardo Maselli, MD, University of California, Davis, US

13:50 – 14:10 **Mechanism of Disease and Therapeutic Rescue of DOK7 in CMS**, Steven Burden, PhD, NYU Langone Health, US

14:10 – 14:30 **Pediatric MG**, Emmanuelle Tiongon, MD, Children's Hospital of Los Angeles, US

14:30 – 14:50 **B-adrenergic Treatment**, David Beeson, MA, PhD, Nuffield Department of Clinical Neurosciences, UK

Question & Answer

15:10 - 15:40 **Coffee Break** (RIVERWALK)

15:40 – 16:20 **Session 4: Tolerance Induction** (REGENCY BALLROOM)

Chair: Amelia Evoli, MD, Università Cattolica Del Sacro Cuore, Italy

15:40 – 16:00 **Preclinical Study of an Antigen-Specific Therapy for the Treatment of MG**, Konstantinos Lazaridis, PhD, Hellenic Pasteur Institute, Greece

16:00 – 16:20 **Oral Tolerance of MuSK EAMG**, Debby Reuveni, MD, Weizmann Institute of Science, Israel
Question and Answer

16:20 **Closing**

16:45 - 17:45 **Special Session: MGNet Outcome Measure Training** (REGENCY BALLROOM)

18:00 - 19:30 **Poster Session 2** (REGENCY BALLROOM)

Thursday, May 12, 2022

7:00 – 8:00 **Breakfast** (RIVERWALK)
Clinical Trainee Breakfast (HIBISCUS B)

8:00 – 8:05 **Welcome** Kevin O'Connor, PhD, Yale School of Medicine, US (REGENCY BALLROOM)

8:05 – 10:00 **Session 1: Abstract Submissions - Platform Presentations** (REGENCY BALLROOM) (Same zoom link as above)

Chairs: Carolina Barnett-Tapia, MD, PhD, Toronto General Hospital, Canada and
Kevin O'Connor, PhD, Yale School of Medicine, US

8:05 – 8:13 **B Cell Related Predictive Biomarkers Of Treatment Response In Myasthenia Gravis**, Valentina Damato, MD, Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome and Department of Neurosciences Drugs and Child Health, University of Florence, Florence, Italy

8:15 – 8:23 **Dysgammaglobulinemia In Musk Myasthenia Gravis Patients**, Dana Vergoossen, Leiden University Medical Center, Netherlands

8:25 – 8:33 **Introducing the Pediatric Myasthenia Gravis Consortium**, Jonathan Strober, MD, University of San Francisco, US

8:35 – 8:43 **Conditioned Mesenchymal Stromal Cells As Tools For Immunomodulation In Myasthenia Gravis**, Alexandra Bayer Wildberger, Sorbonne Université, France

8:45 – 8:53 **Dok7-Aav Improved Acetylcholine Deficiency Cms In A Mouse Model And Enhanced The Effectiveness Of Pyridostigmine Treatment**, Yin Yao Dong, PhD, Nuffield Department of Clinical Neurosciences, UK

8:55 – 9:03 **Five Decades Of Epidemiology In Myasthenia Gravis: Data From Two Italian Mg Referral Centers**, Silvia Falso, PhD, Policlinico Universitario Agostino Gemelli, Italy

- 9:05 – 9:13 **B Cells From Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis Patients Show Increased Frequencies Of Cd20 Low And Cxcr5 Negative Populations**, Patricia Sikorski, PhD, George Washington University, Washington DC, US
- 9:15 – 9:23 **A Population-Based Cohort Study Of Pregnancy Outcomes In Women With Myasthenia Gravis**, Carolina Barnett-Tapia, MD, PhD, Toronto General Hospital, US
- 9:25 – 9:33 **Mri Of The Extra-Ocular Muscles In Myasthenia Gravis Show Small Volume And Fat Fraction Increases**, Kevin Keene, Leiden University Medical Center, Netherlands
- 9:35 – 9:43 **Effects of IgG1-MuSK Antibodies on the Agrin-Induced AChR Clustering Pathway**, Michelangelo Cao, MD, PhD, University of Oxford, UK

10:00 - 10:30 **Break (RIVERWALK)**

10:30 – 12:00 **Session 2: Hot Topics I (REGENCY BALLROOM)**

Chair: James Howard Jr., MD, University of North Carolina, Chapel Hill, US

10:30 – 10:50 **PROMISE MG**, Pushpa Narayanaswami, MD, FAAN, Harvard School of Medicine, US

10:50 – 11:10 **Drug Pricing**, A.Gordon Smith, MD, Virginia Commonwealth University, US

11:10 – 11:30 **ICER - Health Economic Assessment of New Drugs for MG**, Foluso Agboola, MBBS, MPH, Institute for Clinical and Economic Review, US

Question and Answer

12:00 - 13:30 **Lunch (RIVERWALK)**

13:30 – 15:20 **Session 3: Hot Topics II (REGENCY BALLROOM)**

Chair: Anna Punga, MD, PhD

13:30 – 13:50 **CARE MG**, Srikanth Muppidi, MD, Stanford University, US

13:50 – 14:10 **Exercise in MG RCT**, Simone Birnbaum, PhD, Institute of Myology, France

14:10 – 14:30 **Prednisone Taper RCT**, Tarek Sharshar, MD, PhD, Institut Pasteur, France

14:30 – 14:50 **Checkpoint Inhibitor NMJ Disease**, Amanda Guidon, MD, Massachusetts General Hospital, US

Question and Answer

15:20 **Closing** - Samantha Masterson, President and CEO, Myasthenia Gravis Foundation of America (Same link as above)

Program subject to change.